Loading…
Employees: 2,304
Size Chongkundang (185750.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $611M, the 302nd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩63,000 on 6 Nov 2026.
Performance Over six months the shares fell 26.5%, against -21.0% for the median peer and -24.5% for the South Korea market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 7.2% over the last twelve months (peer median -1.7%); the operating margin is 4.3% (peer median 5.0%).
Valuation It trades at 12.6× forward earnings against a peer median of 10.9× (5th most expensive of 10).
Capital Return on invested capital runs 0.0 points below its cost of capital (5.1% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.78T | ₩1.69T | ₩1.59T | ₩1.67T | ₩1.49T |
| Revenue growth | — | +7% | -5% | +12% | — |
| Gross profit | ₩522B | ₩517B | ₩524B | ₩655B | ₩537B |
| EBITDA | ₩123B | ₩125B | ₩139B | ₩284B | ₩144B |
| Net income | ₩79.5B | ₩77.5B | ₩109B | ₩213B | ₩81.0B |
| Free cash flow | -₩65.4B | -₩73.5B | ₩25.8B | ₩277B | ₩23.2B |
| Capital expenditure | ₩252B | ₩179B | ₩66.1B | ₩68.8B | ₩52.7B |
| Total debt | ₩437B | ₩368B | ₩188B | ₩220B | ₩236B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 185750.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.8% | -7.4% | 8th highest of 21 |
| 6-month return | -26.5% | -21.0% | 5th lowest of 21 |
| Distance from 52-week high | -35.8% | -36.2% | 9th highest of 21 |
| Revenue growth (TTM) | +7.2% | -1.7% | 7th highest of 18 |
| Operating margin | 4.3% | 5.0% | 7th lowest of 18 |
| Forward P/E | 12.6× | 10.9× | 5th most expensive of 10 |
| ROIC minus cost of capital | -0.0 pp | -0.8 pp | 8th highest of 17 |
| EV / EBITDA | 7.7× | 19.3× | 2nd cheapest of 6 |
| Net debt / EBITDA | 0.9× | 1.1× | 3rd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 12.6× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 10.9× | -14.3% | +2.8% |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | n/a | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 30.4× | 25.4% | +31.4% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 9.7× | -3.2% | +4.1% |
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 10.9× | -11.1% | +8.8% |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | n/a | n/a | n/a |
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 23.6× | 27.9% | +15.8% |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | n/a | n/a | n/a |
| Jinhe Biotechnology 002688.SZ | China | $587M | -22% | +9% | 5% | 9.5× | 14.8% | +9.7% |
| Jinling Pharmaceutical 000919.SZ | China | $586M | -14% | -8% | 1% | n/a | 5.0% | +5.0% |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 7.1× | -4.9% | +6.5% |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | n/a | 5.5% | -1.1% |
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | n/a | 12.1% | -5.9% |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 5% | 30.1× | 23.2% | +21.9% |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 34.2× | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | n/a | 1.1% | -1.6% |